1,728 results on '"Amza A"'
Search Results
2. Simplified dosing of oral azithromycin for children 1–11 months old in child survival programmes: age-based and height-based dosing protocols
- Author
-
Catherine E Oldenburg, Thomas M Lietman, Ali Sie, Kieran S O'Brien, Elodie Lebas, Mamadou Bountogo, Jessica Brogdon, Valentin Boudo, Amza Abdou, Paul Emerson, Huiyu Hu, Ahmed Mamane Arzika, Ramatou Maliki, Alio Karamba Mankara, Mamadou Outtara, Fanny Yago-Wienne, Issouf Bamba, Charles Knirsch, PJ Hooper, and Fanice Nyatigo
- Subjects
Medicine (General) ,R5-920 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Background To facilitate mass distribution of azithromycin, trachoma control programmes use height instead of weight to determine dose for children 6 months to 15 years old. WHO has recommended azithromycin distribution to children 1–11 months old to reduce mortality in high mortality settings under carefully monitored conditions. Weight was used to determine dose in children 1–5 months old in studies of azithromycin distribution for child survival, but a simplified approach using age or height for all aged 1–11 months old could increase programme efficiency in real-world settings.Methods This secondary analysis used data from two cluster randomised trials of azithromycin distribution for child mortality in Niger and Burkina Faso. An exhaustive search algorithm was developed to determine the optimal dose for different age groups, using tolerance limits of 10–20 mg/kg for children 1–2 months old and 15–30 mg/kg for children 3–11 months old. Height-based dosing was evaluated against the existing trachoma dosing pole and with a similar exhaustive search.Results The optimal two-tiered age-based approach suggested a dose of 80 mg (2 mL) for children 1–2 months old and 160 mg (4 mL) for children 3–11 months old. Under this schedule, 89%–93% of children would have received doses within tolerance limits in both study populations. Accuracy was 93%–94% with a three-tiered approach, which resulted in doses of 80 mg (2 mL), 120 mg (3 mL) and 160 mg (4 mL) for children 1–2, 3–4 and 5–11 months old, respectively. For children 1–5 months old, the existing height pole would result in 70% of doses within tolerance limits. The optimisation identified height-based dosing options with 95% accuracy, although this would require changes to the existing dosing pole as well as additional training to measure infants lying flat.Conclusions Overall, an age-based approach with two age tiers resulted in high accuracy while considering both concerns about overdosing in this young population and simplicity of field operations.
- Published
- 2022
- Full Text
- View/download PDF
3. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders
- Author
-
Henry Lowe, Ngeh Toyang, Blair Steele, Justin Grant, Amza Ali, Lorenzo Gordon, and Wilfred Ngwa
- Subjects
psilocybin ,psychedelic ,neuropharmaceuticals ,neurotherapeutics ,addiction ,anxiety ,Organic chemistry ,QD241-441 - Abstract
The word “psychedelic” (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic drugs such as N,N-DMT/DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamide), MDMA (3,4-methylenedioxymethamphetamine) and psilocybin have had significant value as an entheogen in spiritual, religious (shamanic) and sociocultural rituals in Central and South American cultures for thousands of years. In the 1960s, the globalization of these drugs and their subsequent spread outside of their indigenous, old-world cultures, led to the subsequent implementation of strict drug control laws in many Western countries. Even today, psychedelics are still classified as Schedule I drugs, resulting in a still lingering negative stigmatization/perception, vilification, and ultimate criminalization of psychedelics. This controversy still lingers and still limits scientific research and full medical acceptance. For many years up until recently, the spiritual, religious and medicinal value of these drugs could not be explored in a scientific context. More recently, a second wave of psychedelic research is now focusing on psychedelics as neuropharmaceuticals to treat alcohol and tobacco addiction, general mood and anxiety disorders and cancer-related depression. There is now a vast array of promising evidence-based data to confirm the years of anecdotal evidence of the medicinal values of psychedelics. Natural therapeutic alternatives such as psychedelic drugs may provide a safe and efficacious alternate to conventional drugs used to treat mood and anxiety disorders. In a Western context in particular, psychedelic drugs as therapeutic agents for mood and anxiety disorders are becoming increasingly of interest amidst increasing rates of such disorders globally, changing social constructions, the implementation of government regulations and increasing investment opportunities, that ultimately allow for the scientific study to generate evidenced-based data. Alternative psychotherapeutic interventions are gaining interest also, because of their low physiological toxicity, relatively low abuse potential, safe psychological effects, and no associated persisting adverse physiological or psychological effects during and after use. On the other hand, conventional psychotic drugs and anti-depressants are becoming less favorable because of their adverse side effects. Psychedelic neuropharmaceutical interventions may with medical oversight be the solution to conventional psychiatric disorders such as depression and anxiety, and an alternative to conventional psychiatric treatment options. This paper will review the therapeutic potential of psychedelic drugs as alternative therapeutic options for mood and anxiety disorders in a controlled, clinical setting, where the chances of adverse psychological episodes occurring are mitigated.
- Published
- 2022
- Full Text
- View/download PDF
4. Prolonged mass azithromycin distributions and macrolide resistance determinants among preschool children in Niger: A sub-study of a cluster-randomized trial (MORDOR).
- Author
-
Arzika, Ahmed, Abdou, Amza, Maliki, Ramatou, Beido, Nassirou, Kadri, Boubacar, Harouna, Abdoul, Galo, Abdoul, Alio, Mankara, Lebas, Elodie, Oldenburg, Catherine, OBrien, Kieran, Chen, Cindi, Zhong, Lina, Zhou, Zhaoxia, Yan, Daisy, Hinterwirth, Armin, Doan, Thuy, Porco, Travis, Keenan, Jeremy, and Lietman, Thomas
- Subjects
Humans ,Azithromycin ,Niger ,Child ,Preschool ,Anti-Bacterial Agents ,Infant ,Female ,Drug Resistance ,Bacterial ,Male ,Macrolides ,Mass Drug Administration ,Child Mortality - Abstract
BACKGROUND: Randomized controlled trials found that twice-yearly mass azithromycin administration (MDA) reduces childhood mortality, presumably by reducing infection burden. World Health Organization (WHO) issued conditional guidelines for mass azithromycin administration in high-mortality settings in sub-Saharan Africa given concerns for antibiotic resistance. While prolonged twice-yearly MDA has been shown to increase antibiotic resistance in small randomized controlled trials, the objective of this study was to determine if macrolide and non-macrolide resistance in the gut increases with the duration of azithromycin MDA in a larger setting. METHODS AND FINDINGS: The Macrolide Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) study was conducted in Niger from December 2014 to June 2020. It was a cluster-randomized trial of azithromycin (A) versus placebo (P) aimed at evaluating childhood mortality. This is a sub-study in the MORDOR trial to track changes in antibiotic resistance after prolonged azithromycin MDA. A total of 594 communities were eligible. Children 1 to 59 months in 163 randomly chosen communities were eligible to receive treatment and included in resistance monitoring. Participants, staff, and investigators were masked to treatment allocation. At the conclusion of MORDOR Phase I, by design, all communities received an additional year of twice-yearly azithromycin treatments (Phase II). Thus, at the conclusion of Phase II, the treatment history (1 letter per 6-month period) for the participating communities was either (PP-PP-AA) or (AA-AA-AA). In Phase III, participating communities were then re-randomized to receive either another 3 rounds of azithromycin or placebo, thus resulting in 4 treatment histories: Group 1 (AA-AA-AA-AA-A, N = 51), Group 2 (PP-PP-AA-AA-A, N = 40), Group 3 (AA-AA-AA-PP-P, N = 27), and Group 4 (PP-PP-AA-PP-P, N = 32). Rectal swabs from each child (N = 5,340) were obtained 6 months after the last treatment. Each child contributed 1 rectal swab and these were pooled at the community level, processed for DNA-seq, and analyzed for genetic resistance determinants. The primary prespecified outcome was macrolide resistance determinants in the gut. Secondary outcomes were resistance to beta-lactams and other antibiotic classes. Communities recently randomized to azithromycin (groups 1 and 2) had significantly more macrolide resistance determinants than those recently randomized to placebo (groups 3 and 4) (fold change 2.18, 95% CI 1.5 to 3.51, Punadj < 0.001). However, there was no significant increase in macrolide resistance in communities treated 4.5 years (group 1) compared to just the most recent 2.5 years (group 2) (fold change 0.80, 95% CI 0.50 to 1.00, Padj = 0.010), or between communities that had been treated for 3 years in the past (group 3) versus just 1 year in the past (group 4) (fold change 1.00, 95% CI 0.78 to 2.35, Padj = 0.52). We also found no significant differences for beta-lactams or other antibiotic classes. The main limitations of our study were the absence of phenotypic characterization of resistance, no complete placebo arm, and no monitoring outside of Niger limiting generalizability. CONCLUSIONS: In this study, we observed that mass azithromycin distribution for childhood mortality among preschool children in Niger increased macrolide resistance determinants in the gut but that resistance may plateau after 2 to 3 years of treatment. Co-selection to other classes needs to be monitored. TRIAL REGISTRATION: NCT02047981 https://classic.clinicaltrials.gov/ct2/show/NCT02047981.
- Published
- 2024
5. District-Level Forecast of Achieving Trachoma Elimination as a Public Health Problem By 2030: An Ensemble Modelling Approach.
- Author
-
Srivathsan, Ariktha, Abdou, Amza, Al-Khatib, Tawfik, Apadinuwe, Sue-Chen, Badiane, Mouctar, Bucumi, Victor, Chisenga, Tina, Kabona, George, Kabore, Martin, Kanyi, Sarjo, Bella, Lucienne, Mpo, Nekoua, Masika, Michael, Minnih, Abdellahi, Sitoe, Henis, Mishra, Sailesh, Olobio, Nicholas, Omar, Fatma, Phiri, Isaac, Sanha, Salimato, Seife, Fikre, Sharma, Shekhar, Tekeraoi, Rabebe, Traore, Lamine, Watitu, Titus, Bol, Yak, Borlase, Anna, Deiner, Michael, Renneker, Kristen, Hooper, P, Emerson, Paul, Vasconcelos, Andreia, Arnold, Benjamin, Porco, Travis, Hollingsworth, T, Lietman, Thomas, and Blumberg, Seth
- Subjects
Trachoma ,Humans ,Child ,Preschool ,Infant ,Child ,Disease Eradication ,Prevalence ,Forecasting ,Public Health ,Models ,Statistical ,Mass Drug Administration ,World Health Organization ,Global Health ,Male ,Female - Abstract
Assessing the feasibility of 2030 as a target date for global elimination of trachoma, and identification of districts that may require enhanced treatment to meet World Health Organization (WHO) elimination criteria by this date are key challenges in operational planning for trachoma programmes. Here we address these challenges by prospectively evaluating forecasting models of trachomatous inflammation-follicular (TF) prevalence, leveraging ensemble-based approaches. Seven candidate probabilistic models were developed to forecast district-wise TF prevalence in 11 760 districts, trained using district-level data on the population prevalence of TF in children aged 1-9 years from 2004 to 2022. Geographical location, history of mass drug administration treatment, and previously measured prevalence data were included in these models as key predictors. The best-performing models were included in an ensemble, using weights derived from their relative likelihood scores. To incorporate the inherent stochasticity of disease transmission and challenges of population-level surveillance, we forecasted probability distributions for the TF prevalence in each geographic district, rather than predicting a single value. Based on our probabilistic forecasts, 1.46% (95% confidence interval [CI]: 1.43-1.48%) of all districts in trachoma-endemic countries, equivalent to 172 districts, will exceed the 5% TF control threshold in 2030 with the current interventions. Global elimination of trachoma as a public health problem by 2030 may require enhanced intervention and/or surveillance of high-risk districts.
- Published
- 2024
6. Les déficits visuels chez les conducteurs de taxi dans la ville de Niamey
- Author
-
Hadjia Yakoura Abba Kaka, Roufaye Lamine, Nephthali Gnangourou, and Amza Abdou
- Subjects
conduite automobile ,aptitude visuelle ,déficits visuels ,taxi ,niamey ,Medicine - Abstract
La conduite automobile est réglementée selon la législation qui prévaut dans chaque pays. On peut distinguer des déficits visuels rendant le conducteur inapte à la conduite et ceux compatibles à la conduite automobile. La sécurité routière, celle des usagers et celles des conducteurs passe par une aptitude visuelle optimale. L´évaluation de celle-ci est donc primordiale avant l´octroi du permis de conduire toute catégorie confondue. C´est dans cette optique que les auteurs dans une étude transversale et descriptive du 31 octobre 2016 au 31 janvier 2017 se sont fixé comme objectif d´évaluer la fréquence des déficits visuels chez les conducteurs de taxi dans la capitale Niamey en tenant compte de l´acuité visuelle et du champ visuel. Nous avons inclus les conducteurs de taxi de la ville de Niamey désireux de participer à l´étude à travers le syndicat des conducteurs de taxi, étaient non inclus les anciens chauffeurs de taxis et ceux non consentants à l´étude.
- Published
- 2020
- Full Text
- View/download PDF
7. Cause-specific mortality of children younger than 5 years in communities receiving biannual mass azithromycin treatment in Niger: verbal autopsy results from a cluster-randomised controlled trial
- Author
-
Jeremy D Keenan, ProfMD, Ahmed M Arzika, MPH, Ramatou Maliki, MPH, Sanoussi Elh Adamou, MD, Fatima Ibrahim, RN, Mariama Kiemago, RN, Nana Fatima Galo, RN, Elodie Lebas, RN, Catherine Cook, MPH, Benjamin Vanderschelden, BSc, Robin L Bailey, ProfBM, Sheila K West, ProfPhD, Travis C Porco, ProfPhD, Thomas M Lietman, ProfMD, Paul M Emerson, Jerusha Weaver, Sheila K West, Robin L Bailey, John Hart, Amza Abdou, Boubacar Kadri, Nassirou Beido, E Kelly Callahan, Aisha E Stewart, Ahmed M Arzika, Sanoussi Elh Adamou, Nana Fatima Galo, Fatima Ibrahim, Salissou Kane, Mariama Kiemago, Ramatou Maliki, Catherine Cook, Sun Y Cotter, Thuy Doan, Dionna M Fry, Jeremy D Keenan, Elodie Lebas, Thomas M Lietman, Ying Lin, Kieran S O'Brien, Catherine E Oldenburg, Travis C Porco, Kathryn J Ray, Philip J Rosenthal, George W Rutherford, Benjamin Vanderschelden, Nicole E Varnado, Lina Zhong, and Zhaoxia Zhou
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Summary: Background: The Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) trial found that biannual mass distribution of azithromycin to children younger than 5 years in Niger reduced the primary outcome of all-cause mortality by 18%. We aimed to determine the causes of mortality among deceased children using verbal autopsy. Methods: In this 2-year cluster-randomised controlled trial, 594 community clusters in Niger were randomly allocated (1:1 ratio) to receive biannual mass distributions of either oral azithromycin (approximately 20 mg per kg of bodyweight) or placebo targeted to children aged 1–59 months. Participants, study investigators, and field workers were masked to treatment allocation. Between Nov 23, 2014, and July 31, 2017, 3615 child deaths were recorded by use of biannual house-to-house censuses, and verbal autopsies were done between May 26, 2015, and May 17, 2018, to identify cause of death. Cause-specific mortality, as assessed by verbal autopsy, was a prespecified secondary outcome. This trial is completed and is registered with ClinicalTrials.gov, NCT02047981. Findings: Between Nov 23, 2014, and July 31, 2017, 303 communities (n=40 375 children at baseline) in Niger received mass azithromycin and 291 communities (n=35 747 children at baseline) received placebo. Treatment coverage was 90·3% (SD 10·6) in the azithromycin group and 90·4% (10·1) in the placebo group. No communities were lost to follow-up. In total, 1727 child deaths in the azithromycin group and 1888 child deaths in the placebo group were reported from the population censuses. Of these, the cause of death for 1566 (90·7%) children in the azithromycin group and 1735 (91·9%) children in the placebo group were ascertained by verbal autopsy interviews. In the azithromycin group, 437 (27·9%) deaths were due to malaria, 252 (16·1%) deaths were due to pneumonia, and 234 (14·9%) deaths were due to diarrhoea. In the placebo group, 493 (28·4%) deaths were due to malaria, 275 (15·9%) deaths were due to pneumonia, and 251 (14·5%) deaths were due to diarrhoea. Relative to communities that received placebo, child mortality in communities that received azithromycin was lower for malaria (incidence rate ratio 0·78, 95% CI 0·66–0·92; p=0·0029), dysentery (0·65, 0·44–0·94; p=0·025), meningitis (0·67, 0·46–0·97; p=0·036), and pneumonia (0·83, 0·68–1·00; p=0·051). The distribution of causes of death did not differ significantly between the two study groups (p=0·98). Interpretation: Mass azithromycin distribution resulted in approximately a third fewer deaths in children aged 1–59 months due to meningitis and dysentery, and a fifth fewer deaths due to malaria and pneumonia. The lack of difference in the distribution of causes of death between the azithromycin and placebo groups could be attributable to the broad spectrum of azithromycin activity and the study setting, in which most childhood deaths were due to infections. Funding: Bill & Melinda Gates Foundation.
- Published
- 2020
- Full Text
- View/download PDF
8. The global burden of trichiasis in 2016.
- Author
-
Rebecca M Flueckiger, Paul Courtright, Mariamo Abdala, Amza Abdou, Zaid Abdulnafea, Tawfik K Al-Khatib, Khaled Amer, Olga Nelson Amiel, Sossinou Awoussi, Ana Bakhtiari, Wilfried Batcho, Assumpta Lucienne Bella, Kamal Hashim Bennawi, Simon J Brooker, Brian K Chu, Michael Dejene, Djore Dezoumbe, Balgesa Elkheir Elshafie, Aba Ange Elvis, Djouma Nembot Fabrice, Fatma Juma Omar, Missamou François, Drabo François, Jambi Garap, Michael Gichangi, André Goepogui, Jaouad Hammou, Boubacar Kadri, George Kabona, Martin Kabore, Khumbo Kalua, Mathias Kamugisha, Biruck Kebede, Kaba Keita, Asad Aslam Khan, Genet Kiflu, Makoy Yibi, Garae Mackline, Colin Macleod, Portia Manangazira, Michael P Masika, Marilia Massangaie, Takafira Mduluza, Nabicassa Meno, Nicholas Midzi, Abdallahi Ould Minnih, Sailesh Mishra, Caleb Mpyet, Nicholas Muraguri, Upendo Mwingira, Beido Nassirou, Jean Ndjemba, Cece Nieba, Jeremiah Ngondi, Nicholas Olobio, Alex Pavluck, Isaac Phiri, Rachel Pullan, Babar Qureshi, Boubacar Sarr, Do Seiha, Gloria Marina Serrano Chávez, Shekhar Sharma, Siphetthavong Sisaleumsak, Khamphoua Southisombath, Gretchen Stevens, Andeberhan Tesfazion Woldendrias, Lamine Traoré, Patrick Turyaguma, Rebecca Willis, Georges Yaya, Souleymane Yeo, Francisco Zambroni, Jialiang Zhao, and Anthony W Solomon
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundTrichiasis is present when one or more eyelashes touches the eye. Uncorrected, it can cause blindness. Accurate estimates of numbers affected, and their geographical distribution, help guide resource allocation.MethodsWe obtained district-level trichiasis prevalence estimates in adults for 44 endemic and previously-endemic countries. We used (1) the most recent data for a district, if more than one estimate was available; (2) age- and sex-standardized corrections of historic estimates, where raw data were available; (3) historic estimates adjusted using a mean adjustment factor for districts where raw data were unavailable; and (4) expert assessment of available data for districts for which no prevalence estimates were available.FindingsInternally age- and sex-standardized data represented 1,355 districts and contributed 662 thousand cases (95% confidence interval [CI] 324 thousand-1.1 million) to the global total. Age- and sex-standardized district-level prevalence estimates differed from raw estimates by a mean factor of 0.45 (range 0.03-2.28). Previously non- stratified estimates for 398 districts, adjusted by ×0.45, contributed a further 411 thousand cases (95% CI 283-557 thousand). Eight countries retained previous estimates, contributing 848 thousand cases (95% CI 225 thousand-1.7 million). New expert assessments in 14 countries contributed 862 thousand cases (95% CI 228 thousand-1.7 million). The global trichiasis burden in 2016 was 2.8 million cases (95% CI 1.1-5.2 million).InterpretationThe 2016 estimate is lower than previous estimates, probably due to more and better data; scale-up of trichiasis management services; and reductions in incidence due to lower active trachoma prevalence.
- Published
- 2019
- Full Text
- View/download PDF
9. The Therapeutic Potential of Psilocybin
- Author
-
Henry Lowe, Ngeh Toyang, Blair Steele, Henkel Valentine, Justin Grant, Amza Ali, Wilfred Ngwa, and Lorenzo Gordon
- Subjects
magic mushrooms ,psilocybin ,psychedelic ,neuropharmaceuticals ,neurotherapeutics ,addiction ,Organic chemistry ,QD241-441 - Abstract
The psychedelic effects of some plants and fungi have been known and deliberately exploited by humans for thousands of years. Fungi, particularly mushrooms, are the principal source of naturally occurring psychedelics. The mushroom extract, psilocybin has historically been used as a psychedelic agent for religious and spiritual ceremonies, as well as a therapeutic option for neuropsychiatric conditions. Psychedelic use was largely associated with the “hippie” counterculture movement, which, in turn, resulted in a growing, and still lingering, negative stigmatization for psychedelics. As a result, in 1970, the U.S. government rescheduled psychedelics as Schedule 1 drugs, ultimately ending scientific research on psychedelics. This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as psilocybin. A 2004 pilot study from the University of California, Los Angeles, exploring the potential of psilocybin treatment in patients with advanced-stage cancer managed to reignite interest and significantly renewed efforts in psilocybin research, heralding a new age in exploration for psychedelic therapy. Since then, significant advances have been made in characterizing the chemical properties of psilocybin as well as its therapeutic uses. This review will explore the potential of psilocybin in the treatment of neuropsychiatry-related conditions, examining recent advances as well as current research. This is not a systematic review.
- Published
- 2021
- Full Text
- View/download PDF
10. Comparison of Population-Based Census versus Birth History for the Estimation of Under-5 Mortality in Niger.
- Author
-
Peterson, Brittany, Arzika, Ahmed, Amza, Abdou, Karamba, Alio, Dodo, Nasser, Galo, Nasser, Beidi, Aboubacar, Moustapha, Abarchi, Lebas, Elodie, Cook, Catherine, Keenan, Jeremy, OBrien, Kieran, and Lietman, Thomas
- Subjects
Child ,Humans ,Infant ,Child ,Preschool ,Reproductive History ,Niger ,Censuses ,Child Mortality ,Mass Drug Administration ,Mortality - Abstract
The WHO guidelines on mass distribution of azithromycin for child survival recommend monitoring of mortality to evaluate effectiveness. Trials that contributed evidence to these guidelines used a population-based census to monitor vital status, requiring census workers to visit each household biannually (twice yearly). Birth history is an alternative to the census approach that may be more feasible because it decreases the time and labor needed for mortality monitoring. This study aimed to compare the population-based census (reference standard) and birth history (index test) approaches to estimating mortality among children 1 to 59 months old using data from the Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) trial. Sixteen communities that received 5 years of biannual census in the MORDOR trial were selected randomly also to receive birth history surveys. The census approach recorded more participants and households than birth history, with correlations more than 0.94 for each. The correlation between number of deaths in each community was 0.84 (95% CI, 0.59-0.94). A comparison of the mortality incidence rate estimated from the census against the under-5 mortality rate estimated from the birth history resulted in a correlation of 0.60 (95% CI, 0.15-0.84). Of the 47% of children who were linked individually to compare vital status from each method, the death status of children had a sensitivity of 80% (95% CI, 73-89) and a specificity of 98% (95% CI, 98-99), comparing birth history to census. Overall birth histories were found to be a reasonable alternative to biannual census for tracking vital status.
- Published
- 2023
11. Comprehensive Profile of Pathogens and Antimicrobial Resistance in Conjunctivitis Cases from Niger.
- Author
-
Amza, Abdou, Nassirou, Beido, Kadri, Boubacar, Ali, Saley, Mariama, Boubacar, Ibrahim, Cissé, Roufaye, Lamine, Lebas, Elodie, Colby, Emily, Zhong, Lina, Chen, Cindi, Ruder, Kevin, Yu, Danny, Liu, YuHeng, Abraham, Thomas, Chang, Aaron, Mai, Lina, Hinterwirth, Armin, Seitzman, Gerami, Lietman, Thomas, and Doan, Thuy
- Subjects
Humans ,Anti-Bacterial Agents ,Respiratory Tract Infections ,Niger ,Coinfection ,Epstein-Barr Virus Infections ,Drug Resistance ,Bacterial ,Herpesvirus 4 ,Human ,Conjunctivitis - Abstract
Infectious conjunctivitis outbreaks remain a public health burden. This study focuses on the pathogen and antimicrobial resistance (AMR) profiles identified in Niger. Sixty-two patients with acute infectious conjunctivitis who presented to health posts were enrolled from December 2021 to May 2022. Nasal and conjunctival swabs were obtained from each patient. Unbiased RNA deep sequencing (RNA-seq) was used to identify associated pathogens. A pathogen was identified in 39 patients (63%; 95% CI, 50-74). Of those, an RNA virus was detected in 23 patients (59%; 95% CI, 43-73). RNA viruses were diverse and included human coronaviruses (HCoVs): SARS-CoV-2, HCoV-229E, HCoV-HKU1, and HCoV-OC43. A DNA virus was identified in 11 patients (28%; 95% CI, 17-44). Of those, four patients had a coinfection with an RNA virus and two patients had a coinfection with both an RNA virus and a bacterium. DNA viruses were predominantly human herpesvirus (cytomegalovirus, Epstein-Barr virus, human herpesvirus 8) and human adenovirus species B, C, and F. Eighteen patients (46%; 95% CI, 32-61) had a bacteria-associated infection that included Haemophilus influenza, Haemophilus aegyptius, Staphylococcus aureus, Streptococcus pneumoniae, and Moraxella spp. Antimicrobial resistance determinants were detected in either the conjunctiva or nasal samples of 20 patients (32%; 95% CI, 22-45) and were found to be more diverse in the nose (Shannon alpha diversity, 1.12 [95% CI, 1.05-1.26] versus 1.02 [95% CI, 1.00-1.05], P = 0.01). These results suggest the potential utility of leveraging RNA-seq to surveil pathogens and AMR for ocular infections.
- Published
- 2023
12. Temporal Trends in Phenotypic Macrolide and Nonmacrolide Resistance for Streptococcus pneumoniae Nasopharyngeal Samples Up to 36 Months after Mass Azithromycin Administration in a Cluster-Randomized Trial in Niger.
- Author
-
Hazel, Ashley, Arzika, Ahmed, Abdou, Amza, Lebas, Elodie, Porco, Travis, Maliki, Ramatou, Doan, Thuy, Keenan, Jeremy, Blumberg, Seth, and Lietman, Thomas
- Subjects
Child ,Humans ,Infant ,Azithromycin ,Anti-Bacterial Agents ,Macrolides ,Streptococcus pneumoniae ,Mass Drug Administration ,Niger ,Drug Resistance ,Bacterial - Abstract
Azithromycin mass drug administration decreases child mortality but also selects for antibiotic resistance. Herein, we evaluate macrolide resistance of nasopharyngeal Streptococcus pneumoniae after azithromycin MDA. In a cluster-randomized trial, children 1-59 months received azithromycin or placebo biannually. Fifteen villages from each arm were randomly selected for antimicrobial resistance testing, and 10-15 randomly selected swabs from enrolled children at each village were processed for S. pneumoniae isolation and resistance testing. The primary prespecified outcome was macrolide resistance fraction for azithromycin versus placebo villages at 36 months. Secondary non-prespecified outcomes were comparisons of azithromycin and placebo for: 1) macrolide resistance at 12, 24, and 36 months; 2) nonmacrolide resistance at 36 months; and 3) suspected-erm mutation. At 36 months, 423 swabs were obtained and 322 grew S. pneumoniae, (azithromycin: 146/202, placebo: 176/221). Mean resistance prevalence was non-significantly higher in treatment than placebo (mixed-effects model: 14.6% vs. 8.9%; OR = 2.0, 95% CI: 0.99-3.97). However, when all time points were evaluated, macrolide resistance prevalence was significantly higher in the azithromycin group (β = 0.102, 95% CI: 0.04-0.167). For all nonmacrolides, resistance prevalence at 36 months was not different between the two groups. Azithromycin and placebo were not different for suspected-erm mutation prevalence. Macrolide resistance was higher in the azithromycin group over all time points, but not at 36 months. Although this suggests resistance may not continue to increase after biannual MDA, more studies are needed to clarify when MDA can safely decrease mortality and morbidity in lower- and middle-income countries.
- Published
- 2023
13. Wastewater-Based Surveillance of Antimicrobial Resistance in Niger: An Exploratory Study.
- Author
-
Ousmane, Sani, Kollo, Issifi, Jambou, Ronan, Boubacar, Rakia, Arzika, Ahmed, Maliki, Ramatou, Amza, Abdou, Liu, Zijun, Lebas, Elodie, Colby, Emily, Zhong, Lina, Chen, Cindi, Hinterwirth, Armin, Doan, Thuy, OBrien, Kieran, and Lietman, Thomas
- Subjects
Humans ,Anti-Bacterial Agents ,Drug Resistance ,Bacterial ,Wastewater-Based Epidemiological Monitoring ,Wastewater ,Niger - Abstract
Wastewater-based surveillance is increasingly recognized as an important approach to monitoring population-level antimicrobial resistance (AMR). In this exploratory study, we examined the use of metagenomics to evaluate AMR using untreated wastewater samples routinely collected by the Niger national polio surveillance program. Forty-eight stored samples from two seasons each year over 4 years (2016-2019) in three regions were selected for inclusion in this study and processed using unbiased DNA deep sequencing. Normalized number of reads of genetic determinants for different antibiotic classes were compared over time, by season, and by location. Correlations in resistance were examined among classes. Changes in reads per million per year were demonstrated for several classes, including decreases over time in resistance determinants for phenicols (-3.3, 95% CI: -8.7 to -0.1, P = 0.029) and increases over time for aminocoumarins (3.8, 95% CI: 0.0 to 11.4, P = 0.043), fluoroquinolones (6.8, 95% CI: 0.0 to 20.5, P = 0.048), and beta-lactams (0.85, 95% CI: 0.1 to 1.7, P = 0.006). Sulfonamide resistance was higher in the post-rainy season compared with the dry season (5.2-fold change, 95% CI: 3.4 to 7.9, P < 0.001). No differences were detected when comparing other classes by season or by site for any antibiotic class. Positive correlations were identified in genetic determinants of resistance among several antibiotic classes. These results demonstrate the potential utility of leveraging existing wastewater sample collection in this setting for AMR surveillance.
- Published
- 2023
14. The distribution of the prevalence of ocular chlamydial infection in communities where trachoma is disappearing
- Author
-
Thomas M. Lietman, Teshome Gebre, Amza Abdou, Wondu Alemayehu, Paul Emerson, Seth Blumberg, Jeremy D. Keenan, and Travis C. Porco
- Subjects
Trachoma ,Eradication ,Mass drug administration ,Transmission model ,Geometric distribution ,Infectious and parasitic diseases ,RC109-216 - Abstract
Mathematical models predict that the prevalence of infection in different communities where an infectious disease is disappearing should approach a geometric distribution. Trachoma programs offer an opportunity to test this hypothesis, as the World Health Organization (WHO) has targeted trachoma to be eliminated as a public health concern by the year 2020. We assess the distribution of the community prevalence of childhood ocular chlamydia infection from periodic, cross-sectional surveys in two areas of Ethiopia. These surveys were taken in a controlled setting, where infection was documented to be disappearing over time. For both sets of surveys, the geometric distribution had the most parsimonious fit of the distributions tested, and goodness-of-fit testing was consistent with the prevalence of each community being drawn from a geometric distribution. When infection is disappearing, the single sufficient parameter describing a geometric distribution captures much of the distributional information found from examining every community. The relatively heavy tail of the geometric suggests that the presence of an occasional high-prevalence community is to be expected, and does not necessarily reflect a transmission hot spot or program failure. A single cross-sectional survey can reveal which direction a program is heading. A geometric distribution of the prevalence of infection across communities may be an encouraging sign, consistent with a disease on its way to eradication.
- Published
- 2015
- Full Text
- View/download PDF
15. AUDIBLE: A Convolution-Based Resource Allocator for Oversubscribing Burstable Virtual Machines.
- Author
-
Seyed Ali Jokar Jandaghi, Kaveh Mahdaviani, Amirhossein Mirhosseini, Sameh Elnikety, Cristiana Amza, and Bianca Schroeder
- Published
- 2024
- Full Text
- View/download PDF
16. Monitoring transmission intensity of trachoma with serology.
- Author
-
Tedijanto, Christine, Solomon, Anthony W, Martin, Diana L, Nash, Scott D, Keenan, Jeremy D, Lietman, Thomas M, Lammie, Patrick J, Aiemjoy, Kristen, Amza, Abdou, Aragie, Solomon, Arzika, Ahmed M, Callahan, E Kelly, Carolan, Sydney, Dawed, Adisu Abebe, Goodhew, E Brook, Gwyn, Sarah, Hammou, Jaouad, Kadri, Boubacar, Kalua, Khumbo, Maliki, Ramatou, Nassirou, Beido, Seife, Fikre, Tadesse, Zerihun, West, Sheila K, Wittberg, Dionna M, Zeru Tadege, Taye, and Arnold, Benjamin F
- Subjects
Humans ,Chlamydia trachomatis ,Trachoma ,Antibodies ,Bacterial ,Antigens ,Bacterial ,Prevalence ,Seroepidemiologic Studies ,Child ,Child ,Preschool ,Infant ,Pediatric Research Initiative ,Eye Disease and Disorders of Vision ,Infectious Diseases ,Detection ,screening and diagnosis ,Aetiology ,2.2 Factors relating to the physical environment ,4.1 Discovery and preclinical testing of markers and technologies ,Infection ,Good Health and Well Being - Abstract
Trachoma, caused by ocular Chlamydia trachomatis infection, is targeted for global elimination as a public health problem by 2030. To provide evidence for use of antibodies to monitor C. trachomatis transmission, we collated IgG responses to Pgp3 antigen, PCR positivity, and clinical observations from 19,811 children aged 1-9 years in 14 populations. We demonstrate that age-seroprevalence curves consistently shift along a gradient of transmission intensity: rising steeply in populations with high levels of infection and active trachoma and becoming flat in populations near elimination. Seroprevalence (range: 0-54%) and seroconversion rates (range: 0-15 per 100 person-years) correlate with PCR prevalence (r: 0.87, 95% CI: 0.57, 0.97). A seroprevalence threshold of 13.5% (seroconversion rate 2.75 per 100 person-years) identifies clusters with any PCR-identified infection at high sensitivity ( >90%) and moderate specificity (69-75%). Antibody responses in young children provide a robust, generalizable approach to monitor population progress toward and beyond trachoma elimination.
- Published
- 2023
17. Coxsackievirus A24 causing acute conjunctivitis in a 2023 outbreak in Vietnam
- Author
-
Huy Tran, Thao Ha, Linh Hoang, Yen Tran, Kevin Ruder, Lina Zhong, Cindi Chen, YuHeng Liu, Danny Yu, Thomas Abraham, Armin Hinterwirth, Michael Deiner, Travis C. Porco, Thomas M. Lietman, Thuy Doan, Gerami D. Seitzman, Lalitha Prajna, N. Venkatesh Prajna, Ramesh Gunasekaran, Sankalp Singh Sharma, Vishnu Teja, Meenu Chaudhary, Sanjeeta Sitaula, Ali Sié, Boubacar Coulibaly, Mamadou Bountogo, Thanapong Somkijrungroj, Vannarut Satitpitakul, Linh Hoàng Mai, Thảo Hạ Xuân, Cristhian A. Urzua, Fabian Vega, Felipe Salgado, Loreto Cuitino, Fernando Pérez Pérez, Jaime Macías Martínez, Van Charles Lansingh, Sukhumal Thanapaisal, Wipada Laovirojjanakul, George McKie, Program Officer, Kenia Chavez, Travis Redd, Winston Chamberlain, Angel Cheng, Vivien Tham, Wiwan Sansanayudh, Abba Kaka Hajia Yakoura, Abdou Amza, Abdoul Salam Youssoufou Souley, Adam Nouhou Diori, Beido Nassirou, Boubacar Kadri, Boubacar Mariama, Cissé Mamadou Ibrahim, Lamyne Aboubacar Roufaye, Ramatou Boulhassane, Saley Ali, Zakou Abdou, Lee Goren, Irit Bahar, Ruti Sella, Clare Kelliher, Laura Green, Hon Shing Ong, Jod Mehta, Yu-Chi Liu, Benjamin A. Pinsky, De-Kuang Hwang, Nai-Wen Fan, Hong Sheng Chiong, Javier Lacorzana, Maria Cabrera-Aguas, Stephanie Watson, Edmund Tsui, Nina M. Cherian, Rachel Feit-Leichman, Reginald E. Hughes, Jr, Tania Onclinx, Joseph K Privratsky, Carol Yu, Esmeralda McClean, Iliana Molina, David Liu, Elodie Lebas, Emily Colby, Gerami Seitzman, Thomas Lietman, Thuy Doan, Principal Investigator, Travis Porco, Stephen McLeod, Kuniyoshi Kanai, Meredith Whiteside, Steven Yeh, Tolulope Fashina, James Chodosh, Bridgit Tarkap, Jambi N. Garap, Magdalene Mangot, Edwin Amel, Fasihah Taleo, Johnson Kasso, Kalbule Willie, Madopule Nanu, Prudence Rymill, and Anthony W. Solomon
- Subjects
Coxsackievirus ,Epidemic ,Conjunctivitis ,Keratoconjunctivitis (EKC) ,Vietnam ,Infectious and parasitic diseases ,RC109-216 - Abstract
Objectives: To determine the associated pathogen during the 2023 conjunctivitis outbreak in Vietnam Methods: RNA-sequencing was used to identify pathogens before and during the outbreak. Results: 24 patients with infectious conjunctivitis between March and October 2023 from Hai Yen Vision Institute in Vietnam were swabbed. Coxsackievirus A24v was the most common pathogen identified. Phylogenetic analysis of these strains demonstrates similarities to the Coxsackievirus identified in the 2022 India outbreak. Human adenovirus D was also circulating. Ocular findings of tearing, purulence, and itching were common in this outbreak. Conclusions: Multiple viruses can co-circulate during conjunctivitis outbreaks. Hemorrhagic conjunctivitis, commonly associated with coxsackievirus conjunctivitis, was not a common clinical sign in this outbreak. Repeat genetic surveillance, with the notable inclusion of RNA virus detection strategies, is important for outbreak detection.
- Published
- 2024
- Full Text
- View/download PDF
18. Comparison of door-to-door and fixed-point delivery of azithromycin distribution for child survival in Niger: A cluster-randomized trial.
- Author
-
Arzika, Ahmed, Maliki, Ramatou, Amza, Abdou, Karamba, Alio, Gallo, Nasser, Aichatou, Bawa, Sara, Ismael, Beidi, Diallo, Haroun, Laminou, Oumarou, Farissatou, Lebas, Elodie, Peterson, Brittany, Colby, Emily, Nguyen, William, Liu, Zijun, Fitzpatrick, Meagan, OBrien, Kieran, Lietman, Thomas, and Arnold, Benjamin
- Abstract
Recent evidence indicates mass azithromycin distribution reduces under-5 mortality. This intervention is being considered for child survival programs in high mortality sub-Saharan African settings. The delivery approach used in prior studies required a full-time census and distribution team, which is not feasible for most programs. To determine the optimal programmatic approach to delivery, this study aimed to compare treatment coverage, costs, and acceptability of different delivery approaches with existing community health workers (CHWs). This cluster-randomized trial included rural and peri-urban communities in Dosso, Niger (clinicaltrials.gov, NCT04774991). A random sample of 80 eligible communities was randomized 1:1 to biannual door-to-door or fixed-point delivery of oral azithromycin to children 1-59 months old over 1 year. Data analysts alone were masked given the nature of the intervention. The primary outcome was community-level treatment coverage defined as the number of children treated recorded by CHWs divided by the number of eligible children determined using a post-distribution census. Costs were monitored through routine administrative data collection and micro-costing. The census included survey questions on intervention acceptability among caregivers, community leaders, and CHWs. After randomization, 1 community was excluded due to inaccuracies in available administrative data, resulting in 39 communities receiving door-to-door delivery. At the second distribution, community-level mean treatment coverage was 105% (SD 44%) in the door-to-door arm and 92% (SD 20%) in the fixed-point arm (Mean difference 13%, 95% CI -2% to 28%, P-value = 0.08). The total cost per dose delivered was $1.91 in the door-to-door arm and $2.51 in the fixed-point arm. Indicators of acceptability were similar across stakeholder groups in both arms, with most respondents in each group indicating a preference for door-to-door. Overall, door-to-door delivery is the preferred approach to azithromycin distribution in this setting and might reach more children at a lower cost per dose delivered than fixed-point. Trial Registration: clinicaltrials.gov NCT04774991.
- Published
- 2023
19. Human Conjunctival Transcriptome in Acanthamoeba Keratitis: An Exploratory Study
- Author
-
Seitzman, Gerami D., Keenan, Jeremy D., Lietman, Thomas M., Ruder, Kevin, Zhong, Lina, Chen, Cindi, Liu, YuHeng, Yu, Danny, Abraham, Thomas, Hinterwirth, Armin, Doan, Thuy, Seitz, Berthold, Flockerzi, Elias, Daas, Loay, Hamon, Loïc, Bofferding, Max, Berger, Tim, Dail, Yaser Abu, Livny, Eitan, Bahar, Irit, Goren, Lee, Sella, Ruti, Misanjo, Esther, Likongwe, Hendrix, Kalua, Khumbo, Núñez Amaro, Carlos Daniel, Martínez, Jaime Macías, Pérez Pérez, Jose Fernando, Lansingh, Van Charles, Amza, Abdou, Youssouffou Souley, Abdoul Salam, Bachabi, Abdourahame, Diori, Adam Nouhou, Zakari, Adamou, Atto, Aichatou, Hamidou, Bagna, Yacouba, Barazé, Yahaya, Bonkano, Sofo, Fatouma, Abba Kaka, Hadjia Yakoura, Bouba Traore, Hassane Amadou, Laouali, Ibrahim Mahaman, Saadou, Issa, Laouali, Kakale, Roufaye, Lamyne, Laminou, Laouali, Sani, Magagi Mamane, Ibrahim, Mahaman, Boubacar, Mariama, Soumana, Mariama, Yacouba, Mayaki Moctar, Hassane, Mijitaba, Issiakou, Moctar, Salifou, Moumouni, Boubacar, Nameywa, Boulhassane, Ramatou, Abdoulaye, Sadiaa, Ali, Seley, Soumana, Yaboubou, Abdou, Zakou, Ong, Hon Shing, Mehta, Jodhbir S., Liu, Yu-Chi, Hollhumer, Roland, Bograd, Alexandra, Tappeiner, Christoph, Goldblum, David, Fan, Nai-Wen, Sangsao, Keeratika, Chokesuwattanaskul, Susama, Satitpitakul, Vannarut, Sansanayudh, Wiwan, Serrano, Andres, Trief, Danielle, Rand, Gabriel, Florakis, George J., Kim, Janice, Suh, Leejee H., Zaffos, Joshua, Potts, Luke, Hirabayashi, Kristin, Redd, Travis, Gang, Anjulie M., Carli, David G., Price, Francis W., Jr, Dudasko, Kathleen N., Price, Marianne O., Feng, Matthew T., Mortensen, Xavier M., Berkowitz, Carla, Tsui, Edmund, Patarajierapun, Promporn, Fung, Simon S. M., Yu, Carol, McClean, Esmeralda, Kim, Philip, Hinterwirth, Armin, Chen, Cindi, Yan, Daisy, Yu, Danny, Lebas, Elodie, Seitzman, Gerami D., Ouimette, Kevin, Zhong, Lina, Deiner, Michael S., Abraham, Thomas, Lietman, Thomas M., Doan, Thuy, Porco, Travis C., Liu, Yuheng, Lin, Amy, Zaugg, Brian, Nuttall, Elizabeth, Gutierrez, Karen, Hu, Katherine S., Kurt, Kevin, Nehls, Sarah, Enright, Jennifer, Walia, Jessica, Thulasi, Praneetha, and McKie, George A.
- Published
- 2024
- Full Text
- View/download PDF
20. Deep sequencing analysis of clinical samples from patients with acute infectious conjunctivitis during the COVID-19 delta surge in Madurai, India
- Author
-
Lalitha, Prajna, Prajna, N Venkatesh, Gunasekaran, Rameshkumar, Teja, Gonugunta Vishnu, Sharma, Sankalp S, Hinterwirth, Armin, Ruder, Kevin, Zhong, Lina, Chen, Cindi, Deiner, Michael, Huang, ChunHong, Pinsky, Benjamin A, Lietman, Thomas M, Doan, Thuy, Seitzman, Gerami D, Prajna, Lalitha, Venkatesh Prajna, N, Gunasekaran, Ramesh, Sharma, Sankalp Singh, Teja, Vishnu, Chaudhary, Meenu, Sitaula, Sanjeeta, Sié, Ali, Coulibaly, Boubacar, Bountogo, Mamadou, Somkijrungroj, Thanapong, Satitpitakul, Vannarut, Tran, Huy, Mai, Linh Hoàng, Xuân, Thảo Hạ, Tran, Yen, Urzua, Cristhian A, Vega, Fabian, Salgado, Felipe, Cuitino, Loreto, Lopez, Emiliano Sebastian, Gimeno, Federico Luengo, Jaeschke, Tomas, Pérez, Fernando Pérez, Martínez, Jaime Macías, Lansingh, Van Charles, Thanapaisal, Sukhumal, Laovirojjanakul, Wipada, McKie, George, Chavez, Kenia, Redd, Travis, Chamberlain, Winston, Cheng, Angel, Tham, Vivien, Sansanayudh, Wiwan, Yakoura, Abba Kaka Hajia, Amza, Abdou, Souley, Abdoul Salam Youssoufou, Diori, Adam Nouhou, Nassirou, Beido, Kadri, Boubacar, Mariama, Boubacar, Ibrahim, Cissé Mamadou, Roufaye, Lamyne Aboubacar, Boulhassane, Ramatou, Ali, Saley, Abdou, Zakou, Goren, Lee, Sella, Ruti, Kelliher, Clare, Green, Laura, Ong, Hon Shing, Mehta, Jod, Liu, Yu-Chi, Hwang, De-Kuang, Fan, Nai-Wen, Chiong, Hong Sheng, Lacorzana, Javier, Cabrera-Aguas, Maria, Watson, Stephanie, Tsui, Edmund, Ramirez, Joana, Cherian, Nina M, Feit-Leichman, Rachel, Hughes, Reginald E, Onclinx, Tania, Yu, Carol, McClean, Esmeralda, Molina, Iliana, Yu, Danny, Liu, David, Lebas, Elodie, Colby, Emily, Seitzman, Gerami, Abraham, Thomas, Lietman, Thomas, Porco, Travis, and McLeod, Stephen
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Clinical Trials and Supportive Activities ,Emerging Infectious Diseases ,Infectious Diseases ,Vaccine Related ,Eye Disease and Disorders of Vision ,Infection ,Good Health and Well Being ,Humans ,COVID-19 ,SARS-CoV-2 ,Prospective Studies ,India ,Conjunctivitis ,Adenoviruses ,Human ,Acute Disease ,High-Throughput Nucleotide Sequencing ,SCORPIO (Seasonal Conjunctivitis Outbreak Reporting for Prevention and Improved Outcomes) Study Group ,Microbiology ,Medical Microbiology ,Virology ,Clinical sciences ,Medical microbiology - Abstract
BackgroundSeasonal outbreaks of infectious conjunctivitis remain a public health issue. Determination of outbreak etiologies in the context of a worldwide pandemic may provide useful information to guide public health strategies. The aim of this study was to identify pathogens associated with outpatient infectious conjunctivitis during the COVID-19 Delta surge.MethodsThis prospective study was conducted from April 2021 to September 2021. All outpatients presenting to the Aravind Eye Center (Madurai, India) with signs and symptoms consistent with acute infectious conjunctivitis were eligible. Three swabs were obtained from each participant: one from each conjunctiva and one from the anterior nares. Samples were processed for metagenomic RNA deep sequencing (RNA-seq).ResultsSamples from 106 study participants were sequenced. The most common presenting symptoms were tearing (86%) and itching (71%). Preauricular lymphadenopathy was present in 38% of participants. 20% of participants had close contacts with similar symptoms. Systemic symptoms such as coughing, runny nose, vomiting or diarrhea were uncommonly reported. 60% of all participants used some medicated eye drops upon enrollment. 75% of study participants demonstrated infection with human adenovirus D (HAdV-D). 11% of conjunctivitis was associated with SARS-CoV-2. 15% had no definitive pathogen detected. 8% of all participants had codetection of more than one pathogen on RNA-seq.ConclusionsDuring the COVID-19 Delta surge in India, HAdV-D was the most common pathogen associated with infectious conjunctivitis. SARS-CoV-2 was the second most common associated pathogen. Seasonal surveillance may be necessary for the determination of emerging and reemerging pathogens responsible for infectious conjunctivitis.
- Published
- 2022
21. Simplified dosing of oral azithromycin for children 1–11 months old in child survival programmes: age-based and height-based dosing protocols
- Author
-
Hu, Huiyu, Arzika, Ahmed Mamane, Sie, Ali, Abdou, Amza, Maliki, Ramatou, Mankara, Alio Karamba, Outtara, Mamadou, Bountogo, Mamadou, Boudo, Valentin, Yago-Wienne, Fanny, Bamba, Issouf, Knirsch, Charles, Emerson, Paul, Hooper, PJ, Lebas, Elodie, Brogdon, Jessica, Nyatigo, Fanice, Oldenburg, Catherine E, Lietman, Thomas M, and O'Brien, Kieran S
- Subjects
Health Services and Systems ,Public Health ,Health Sciences ,Pediatric ,Clinical Research ,Clinical Trials and Supportive Activities ,Good Health and Well Being ,Anti-Bacterial Agents ,Azithromycin ,Body Height ,Child ,Child Mortality ,Humans ,Infant ,Trachoma ,child health ,public health ,Health services and systems ,Public health - Abstract
BackgroundTo facilitate mass distribution of azithromycin, trachoma control programmes use height instead of weight to determine dose for children 6 months to 15 years old. WHO has recommended azithromycin distribution to children 1-11 months old to reduce mortality in high mortality settings under carefully monitored conditions. Weight was used to determine dose in children 1-5 months old in studies of azithromycin distribution for child survival, but a simplified approach using age or height for all aged 1-11 months old could increase programme efficiency in real-world settings.MethodsThis secondary analysis used data from two cluster randomised trials of azithromycin distribution for child mortality in Niger and Burkina Faso. An exhaustive search algorithm was developed to determine the optimal dose for different age groups, using tolerance limits of 10-20 mg/kg for children 1-2 months old and 15-30 mg/kg for children 3-11 months old. Height-based dosing was evaluated against the existing trachoma dosing pole and with a similar exhaustive search.ResultsThe optimal two-tiered age-based approach suggested a dose of 80 mg (2 mL) for children 1-2 months old and 160 mg (4 mL) for children 3-11 months old. Under this schedule, 89%-93% of children would have received doses within tolerance limits in both study populations. Accuracy was 93%-94% with a three-tiered approach, which resulted in doses of 80 mg (2 mL), 120 mg (3 mL) and 160 mg (4 mL) for children 1-2, 3-4 and 5-11 months old, respectively. For children 1-5 months old, the existing height pole would result in 70% of doses within tolerance limits. The optimisation identified height-based dosing options with 95% accuracy, although this would require changes to the existing dosing pole as well as additional training to measure infants lying flat.ConclusionsOverall, an age-based approach with two age tiers resulted in high accuracy while considering both concerns about overdosing in this young population and simplicity of field operations.
- Published
- 2022
22. Aquaporin-4 Immuneglobulin G testing in 36 consecutive Jamaican patients with inflammatory central nervous system demyelinating disease
- Author
-
Sherri Sandy, Sean J. Pittock, Terence A.R. Seemungal, and Amza Ali
- Subjects
AQP4/NMO-IgG, neuroimmunology, neuromyelitis optica, multiple sclerosis, tropical neurology ,Medicine ,Internal medicine ,RC31-1245 ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Epidemiological studies of neuromyelitis optica (NMO) in Jamaica are lacking. Here we reviewed the clinical records of 700 patients undergoing neurological evaluation at the Kingston Public Hospital, the largest tertiary institution in Jamaica over a 4 month period. We investigated the diagnostic utility of Aquaporin-4 ImmuneglobulinG (AQP4-IgG) testing in 36 consecutive patients with a diagnosis of an inflammatory demyelinating disorder (IDD) of the central nervous system (CNS). Patients were classified into 3 categories: i) NMO, n=10; ii) multiple sclerosis (MS), n=14 and iii) unclassified IDD (n=12). All sera were tested for AQP-IgG status by cell binding assay (Euroimmun). No MS cases were positive. Ninety per cent of NMO cases were positive. Four of 12 patients with unclassified IDD tested positive for AQP4-IgG. AQP4-IgG seropositivity was associated with a lower socioeconomic status, higher EDSS (P=0.04) and lower pulmonary function than the seronegative cases (P=0.007). Aquaporin-4 autoimmunity may account for a significant proportion of Jamaican CNS IDDs.
- Published
- 2014
- Full Text
- View/download PDF
23. Impact of biannual mass azithromycin treatment on enteropathogen carriage in children younger than 5 years in Niger
- Author
-
Platts-Mills, James A, Ayoub, Elias, Zhang, Jixian, McQuade, Elizabeth T Rogawski, Arzika, Ahmed Mamane, Maliki, Ramatou, Abdou, Amza, Keenan, Jeremy D, Lietman, Thomas M, Liu, Jie, and Houpt, Eric R
- Subjects
Emerging Infectious Diseases ,Infectious Diseases ,Clinical Trials and Supportive Activities ,Biotechnology ,Clinical Research ,Good Health and Well Being ,Anti-Bacterial Agents ,Azithromycin ,Child ,Child ,Preschool ,Humans ,Infant ,Mass Drug Administration ,Niger ,Prevalence ,enteropathogens ,Shigella ,Shigella ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Abstract
We analyzed samples obtained at baseline and 24 months in a mass azithromycin administration trial in Niger using quantitative polymerase chain reaction. In villages randomized to azithromycin, Shigella was the only pathogen reduced at 24 months (prevalence ratio, 0.36 [95% confidence interval: .17-.79]; difference in log quantity, -.42 [-.75 to -.10]).
- Published
- 2022
24. Fostering Engineering Education 4.0 Paradigm Facing the Pandemic and VUCA World.
- Author
-
Monica Ionita Ciolacu, Bogdan Mihailescu, Tamara Rachbauer, Christina Hansen, Catalin Gheorghe Amza, and Paul Svasta
- Published
- 2023
- Full Text
- View/download PDF
25. Natural vs. Synthetic Psilocybin: The Same or Completely Different?
- Author
-
Ali, Amza, Gifford, Mary-Elizabeth, Lowe, Henry, Gordon, Lorenzo, Grant, Justin, Agrawal, Dinesh Chandra, editor, and Dhanasekaran, Muralikrishnan, editor
- Published
- 2023
- Full Text
- View/download PDF
26. The WHO Mental Health Gap Action Programme for mental, neurological, and substance use conditions: the new and updated guideline recommendations
- Author
-
Ali, Amza, Assanangkornchai, Sawitri, Brodaty, Henry, Carli, Vladimir, El Chammay, Rabih, Chang, Odille, Collins, Pamela Y, Cuijpers, Pim, Dowrick, Christopher, Eaton, Julian, Ferri, Cleusa P, Fortes, Sandra, Hengartner, Michael P, Humayun, Asma, Jette, Nathalie, de Vries, Petrus J, Medina-Mora, Maria Elena, Murthy, Pratima, Nadera, Dinah, Newton, Charles, Njenga, Michael, Omigbodun, Olayinka, Rahimi-Movaghar, Afarin, Rahman, Atif, Fortunato dos Santos, Palmira, Saxena, Shekhar, Vijayakumar, Lakshmi, Wang, Huali, Wattanavitukul, Pichayanan, Yewnetu, Enat, Carswell, Ken, Chatterjee, Sudipto, Fatima, Batool, Fleischmann, Alexandra, Gray, Brandon, Hanlon, Charlotte, Hanna, Fahmy, Krupchanka, Dzmitry, Malik, Aiysha, van Ommeren, Mark, Poznyak, Vladimir, Seeher, Katrin, Servili, Chiara, Weissbecker, Inka, Baingana, Florence, Alfonzo Bello, Luis, Bruni, Andrea, Jorge Dos Santos Ferreira Borges Bigot, Ana Carina, Dorji, Chencho, Vandendyck, Martin, Lazeri, Ledia, Monteiro, Maristela Goldnadel, Rani, Manju, Saeed, Khalid, e Souza, Renato Oliveira, Ameyan, Wole, Baltag, Valentina, Branca, Francesco, Cappello, Bernadette, Cometto, Giorgio, Dalil, Suraya, Gabrielli, Albis, Huttner, Benedikt, Jaramillo, Ernesto, Khan, Taskeen, King, Jonathan, Krech, Ruediger, Roebbel, Nathalie, Tran, Nhan, Sumi, Yuka, Brohan, Elaine, Chowdhary, Neerja, Dua, Tarun, Barbui, Corrado, Thornicroft, Graham, and Kestel, Dévora
- Published
- 2024
- Full Text
- View/download PDF
27. Azithromycin Reduction to Reach Elimination of Trachoma (ARRET): study protocol for a cluster randomized trial of stopping mass azithromycin distribution for trachoma
- Author
-
Amza, Abdou, Kadri, Boubacar, Nassirou, Beido, Arzika, Ahmed M, Austin, Ariana, Nyatigo, Fanice, Lebas, Elodie, Arnold, Benjamin F, Lietman, Thomas M, and Oldenburg, Catherine E
- Subjects
Clinical Trials and Supportive Activities ,Eye Disease and Disorders of Vision ,Clinical Research ,Good Health and Well Being ,Anti-Bacterial Agents ,Azithromycin ,Chlamydia trachomatis ,Humans ,Infant ,Prevalence ,Randomized Controlled Trials as Topic ,Trachoma ,Pediatric Research Initiative ,Infectious Diseases ,Pediatric ,Prevention ,Aetiology ,2.4 Surveillance and distribution ,Infection ,Adolescent ,Anti-Infective Agents ,Antibodies ,Bacterial ,Child ,Child ,Preschool ,Cross-Sectional Studies ,Endemic Diseases ,Eye Infections ,Bacterial ,Female ,Follow-Up Studies ,Forecasting ,Male ,Nepal ,Population Surveillance ,Retrospective Studies ,Withholding Treatment ,Mass drug administration ,Neglected tropical diseases ,Opthalmology and Optometry ,Ophthalmology & Optometry - Abstract
BackgroundThe World Health Organization (WHO) recommends annual mass azithromycin distribution until districts drop below 5% prevalence of trachomatous inflammation-follicular (TF). Districts with very low TF prevalence may have little or no transmission of the ocular strains of Chlamydia trachomatis that cause trachoma, and additional rounds of mass azithromycin distribution may not be useful. Here, we describe the protocol for a randomized controlled trial designed to evaluate whether mass azithromycin distribution can be stopped prior to the current WHO guidelines.MethodsThe Azithromycin Reduction to Reach Elimination of Trachoma (ARRET) study is a 1:1 community randomized non-inferiority trial designed to evaluate whether mass azithromycin distribution can be stopped in districts with baseline prevalence of TF under 20%. Communities in Maradi, Niger are randomized after baseline assessment either to continued annual mass azithromycin distribution or stopping annual azithromycin distribution over a 3-year period. We will compare the prevalence of ocular C. trachomatis (primary outcome), TF and other clinical signs of trachoma, and serologic markers of trachoma after 3 years. We hypothesize that stopping annual azithromycin distribution will be non-inferior to continued annual azithromycin distributions for all markers of trachoma prevalence and transmission.DiscussionThe results of this trial are anticipated to provide potentially guideline-changing evidence for when mass azithromycin distributions can be stopped in low TF prevalence areas. TRIAL REGISTRATION NUMBER: This study is registered at clinicaltrials.gov ( NCT04185402 ). Registered December 4, 2019; prospectively registered pre-results.
- Published
- 2021
28. Gut resistome of preschool children after prolonged mass azithromycin distribution: a cluster-randomized trial
- Author
-
Arzika, Ahmed M, Maliki, Ramatou, Abdou, Amza, Mankara, Alio K, Harouna, Abdoul N, Cook, Catherine, Hinterwirth, Armin, Worden, Lee, Zhong, Lina, Chen, Cindi, Ruder, Kevin, Zhou, Zhaoxia, Lebas, Elodie, O’Brien, Kieran S, Oldenburg, Catherine E, Le, Victoria, Arnold, Benjamin F, Porco, Travis, Keenan, Jeremy D, Lietman, Thomas M, and Doan, Thuy
- Subjects
Clinical Trials and Supportive Activities ,Pediatric ,Antimicrobial Resistance ,Clinical Research ,Anti-Bacterial Agents ,Azithromycin ,Child ,Preschool ,Drug Resistance ,Bacterial ,Humans ,Macrolides ,Mass Drug Administration ,azithromycin ,antibiotic resistance ,gut resistome ,mass drug distribution ,Niger ,preschool children ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Abstract
We evaluated the gut resistome of children from communities treated with 10 twice-yearly azithromycin distributions. Although the macrolide resistance remained higher in the azithromycin arm, the selection of non-macrolide resistance observed at earlier time points did not persist. Longitudinal resistance monitoring should be a critical component of mass distribution programs.Clinical trials registrationNCT02047981.
- Published
- 2021
29. Can we eradicate trachoma? A survey of stakeholders.
- Author
-
Oldenburg, Catherine E, Aragie, Solomon, Amza, Abdou, Solomon, Anthony W, Brogdon, Jessica, Arnold, Benjamin F, Keenan, Jeremy D, and Lietman, Thomas M
- Subjects
Humans ,Trachoma ,Azithromycin ,Anti-Bacterial Agents ,Health Care Surveys ,Prevalence ,Preventive Health Services ,Health Plan Implementation ,World Health Organization ,Disease Eradication ,Global Health ,Cornea ,Epidemiology ,Infection ,Public health ,Eye Disease and Disorders of Vision ,Clinical Research ,Good Health and Well Being ,Clinical Sciences ,Opthalmology and Optometry ,Public Health and Health Services ,Ophthalmology & Optometry - Abstract
Background/aimsAlthough tremendous progress towards the 2020 goal of global elimination of trachoma as a public health problem has been made, it will not be achieved. Future targets are now being considered. One option is changing the goal to eradication. We surveyed trachoma experts to assess beliefs related to trachoma eradication and determine perceived obstacles to achieving it.MethodsWe conducted a survey at the beginning of a trachoma eradication session at the 2019 Coalition for Operational Research on Neglected Tropical Diseases meeting in National Harbor, Maryland, USA. We asked respondents what the most important goal of azithromycin mass drug administration was for trachoma (control, elimination of infection or eradication) and if and when they believed trachoma eradication would occur. We then asked what the biggest obstacles were to global eradication.ResultsFifty-six surveys were returned (95%). Most (91%) participants reported that the most important goal of azithromycin mass drug administration was control or elimination of infection, and 24% of participants reported that global eradication was not possible. Of the 76% who reported a year by which they believed trachoma could be eradicated, most fell between 2040 and 2050. Commonly cited barriers to global eradication included lack of surveillance tools to confirm eradication or monitor for infection recrudescence (32%) and lack of resources (23%).ConclusionsDevelopment of alternative indicators for trachoma surveillance and continued investment in trachoma programmes, particularly focused support in the most heavily affected populations, might increase enthusiasm for the feasibility of eradication.
- Published
- 2021
30. Stopping azithromycin mass drug administration for trachoma: A systematic review.
- Author
-
Mahmud, Hamidah, Landskroner, Emma, Amza, Abdou, Aragie, Solomon, Godwin, William W, de Hostos Barth, Anna, O'Brien, Kieran S, Lietman, Thomas M, and Oldenburg, Catherine E
- Subjects
Biological Sciences ,Medical and Health Sciences ,Tropical Medicine - Abstract
The World Health Organization (WHO) recommends continuing azithromycin mass drug administration (MDA) for trachoma until endemic regions drop below 5% prevalence of active trachoma in children aged 1-9 years. Azithromycin targets the ocular strains of Chlamydia trachomatis that cause trachoma. Regions with low prevalence of active trachoma may have little if any ocular chlamydia, and, thus, may not benefit from azithromycin treatment. Understanding what happens to active trachoma and ocular chlamydia prevalence after stopping azithromycin MDA may improve future treatment decisions. We systematically reviewed published evidence for community prevalence of both active trachoma and ocular chlamydia after cessation of azithromycin distribution. We searched electronic databases for all peer-reviewed studies published before May 2020 that included at least 2 post-MDA surveillance surveys of ocular chlamydia and/or the active trachoma marker, trachomatous inflammation-follicular (TF) prevalence. We assessed trends in the prevalence of both indicators over time after stopping azithromycin MDA. Of 140 identified studies, 21 met inclusion criteria and were used for qualitative synthesis. Post-MDA, we found a gradual increase in ocular chlamydia infection prevalence over time, while TF prevalence generally gradually declined. Ocular chlamydia infection may be a better measurement tool compared to TF for detecting trachoma recrudescence in communities after stopping azithromycin MDA. These findings may guide future trachoma treatment and surveillance efforts.
- Published
- 2021
31. Measurement of Foveal Retinal Thickness in Myopic Patients Using Different Display Modes on Optical Coherence Tomography: A Retrospective, Cross-Sectional Study
- Author
-
Lawali, Dan Jouma A. Maman, Wu, Guanrong, Guo, Yunxiang, Lin, Zhangjie, Wu, Qiaowei, Amza, Abdou, Du, Zijing, Ren, Yun, Fang, Ying, Dong, Xinran, Hu, Yunyan, Niu, Yongyi, Zhang, Hongyang, Yu, Honghua, Yang, Xiaohong, and Hu, Yijun
- Published
- 2023
- Full Text
- View/download PDF
32. Age-based targeting of biannual azithromycin distribution for child survival in Niger: an adaptive cluster-randomized trial protocol (AVENIR).
- Author
-
O'Brien, Kieran S, Arzika, Ahmed M, Amza, Abdou, Maliki, Ramatou, Ousmane, Sani, Kadri, Boubacar, Nassirou, Beido, Mankara, Alio Karamba, Harouna, Abdoul Naser, Colby, Emily, Lebas, Elodie, Liu, Zijun, Le, Victoria, Nguyen, William, Keenan, Jeremy D, Oldenburg, Catherine E, Porco, Travis C, Doan, Thuy, Arnold, Benjamin F, Lietman, Thomas M, and AVENIR Study Group
- Subjects
AVENIR Study Group ,Humans ,Macrolides ,Azithromycin ,Anti-Bacterial Agents ,Drug Resistance ,Bacterial ,Child ,Child ,Preschool ,Infant ,Niger ,Randomized Controlled Trials as Topic ,Mass Drug Administration ,Adaptive trial ,Cluster-randomized trial ,Mass drug administration ,Mortality ,Public Health ,Public Health and Health Services - Abstract
BackgroundBiannual distribution of azithromycin to children 1-59 months old reduced mortality by 14% in a cluster-randomized trial. The World Health Organization has proposed targeting this intervention to the subgroup of children 1-11 months old to reduce selection for antimicrobial resistance. Here, we describe a trial designed to determine the impact of age-based targeting of biannual azithromycin on mortality and antimicrobial resistance.MethodsAVENIR is a cluster-randomized, placebo-controlled, double-masked, response-adaptive large simple trial in Niger. During the 2.5-year study period, 3350 communities are targeted for enrollment. In the first year, communities in the Dosso region will be randomized 1:1:1 to 1) azithromycin 1-11: biannual azithromycin to children 1-11 months old with placebo to children 12-59 months old, 2) azithromycin 1-59: biannual azithromycin to children 1-59 months old, or 3) placebo: biannual placebo to children 1-59 months old. Regions enrolled after the first year will be randomized with an updated allocation based on the probability of mortality in children 1-59 months in each arm during the preceding study period. A biannual door-to-door census will be conducted to enumerate the population, distribute azithromycin and placebo, and monitor vital status. Primary mortality outcomes are defined as all-cause mortality rate (deaths per 1000 person-years) after 2.5 years from the first enrollment in 1) children 1-59 months old comparing the azithromycin 1-59 and placebo arms, 2) children 1-11 months old comparing the azithromycin 1-11 and placebo arm, and 3) children 12-59 months in the azithromycin 1-11 and azithromycin 1-59 arms. In the Dosso region, 50 communities from each arm will be followed to monitor antimicrobial resistance. Primary resistance outcomes will be assessed after 2 years of distributions and include 1) prevalence of genetic determinants of macrolide resistance in nasopharyngeal samples from children 1-59 months old, and 2) load of genetic determinants of macrolide resistance in rectal samples from children 1-59 months old.DiscussionAs high-mortality settings consider this intervention, the results of this trial will provide evidence to support programmatic and policy decision-making on age-based strategies for azithromycin distribution to promote child survival.Trial registrationThis trial was registered on January 13, 2020 (clinicaltrials.gov: NCT04224987 ).
- Published
- 2021
33. Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution
- Author
-
Doan, Thuy, Worden, Lee, Hinterwirth, Armin, Arzika, Ahmed M, Maliki, Ramatou, Abdou, Amza, Zhong, Lina, Chen, Cindi, Cook, Catherine, Lebas, Elodie, O’Brien, Kieran S, Oldenburg, Catherine E, Chow, Eric D, Porco, Travis C, Lipsitch, Marc, Keenan, Jeremy D, and Lietman, Thomas M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,HIV/AIDS ,Clinical Research ,Pediatric ,Antimicrobial Resistance ,Infectious Diseases ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,Anti-Bacterial Agents ,Azithromycin ,Child Mortality ,Child ,Preschool ,Drug Resistance ,Bacterial ,Female ,Gastrointestinal Microbiome ,Humans ,Infant ,Macrolides ,Male ,Mass Drug Administration ,Metagenome ,Niger ,Sequence Analysis ,DNA ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundMass distribution of azithromycin to preschool children twice yearly for 2 years has been shown to reduce childhood mortality in sub-Saharan Africa but at the cost of amplifying macrolide resistance. The effects on the gut resistome, a reservoir of antimicrobial resistance genes in the body, of twice-yearly administration of azithromycin for a longer period are unclear.MethodsWe investigated the gut resistome of children after they received twice-yearly distributions of azithromycin for 4 years. In the Niger site of the MORDOR trial, we enrolled 30 villages in a concurrent trial in which they were randomly assigned to receive mass distribution of either azithromycin or placebo, offered to all children 1 to 59 months of age every 6 months for 4 years. Rectal swabs were collected at baseline, 36 months, and 48 months for analysis of the participants' gut resistome. The primary outcome was the ratio of macrolide-resistance determinants in the azithromycin group to those in the placebo group at 48 months.ResultsOver the entire 48-month period, the mean (±SD) coverage was 86.6±12% in the villages that received placebo and 83.2±16.4% in the villages that received azithromycin. A total of 3232 samples were collected during the entire trial period; of the samples obtained at the 48-month monitoring visit, 546 samples from 15 villages that received placebo and 504 from 14 villages that received azithromycin were analyzed. Determinants of macrolide resistance were higher in the azithromycin group than in the placebo group: 7.4 times as high (95% confidence interval [CI], 4.0 to 16.7) at 36 months and 7.5 times as high (95% CI, 3.8 to 23.1) at 48 months. Continued mass azithromycin distributions also selected for determinants of nonmacrolide resistance, including resistance to beta-lactam antibiotics, an antibiotic class prescribed frequently in this region of Africa.ConclusionsAmong villages assigned to receive mass distributions of azithromycin or placebo twice yearly for 4 years, antibiotic resistance was more common in the villages that received azithromycin than in those that received placebo. This trial showed that mass azithromycin distributions may propagate antibiotic resistance. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT02047981.).
- Published
- 2020
34. Comparison of anthropometric indicators to predict mortality in a population-based prospective study of children under 5 years in Niger
- Author
-
O’Brien, Kieran S, Amza, Abdou, Kadri, Boubacar, Nassirou, Beido, Cotter, Sun Y, Stoller, Nicole E, West, Sheila K, Bailey, Robin L, Porco, Travis C, Keenan, Jeremy D, Lietman, Thomas M, and Oldenburg, Catherine E
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Health Sciences ,Nutrition and Dietetics ,Obesity ,Pediatric ,Clinical Trials and Supportive Activities ,Clinical Research ,Nutrition ,Zero Hunger ,Good Health and Well Being ,Anthropometry ,Arm ,Body Height ,Body Weight ,Child ,Child Mortality ,Child ,Preschool ,Female ,Humans ,Infant ,Longitudinal Studies ,Male ,Malnutrition ,Niger ,Prospective Studies ,Mortality ,Medical and Health Sciences ,Nutrition & Dietetics ,Biomedical and clinical sciences ,Health sciences - Abstract
ObjectiveIn the present study, we aimed to compare anthropometric indicators as predictors of mortality in a community-based setting.DesignWe conducted a population-based longitudinal study nested in a cluster-randomized trial. We assessed weight, height and mid-upper arm circumference (MUAC) on children 12 months after the trial began and used the trial's annual census and monitoring visits to assess mortality over 2 years.SettingNiger.ParticipantsChildren aged 6-60 months during the study.ResultsOf 1023 children included in the study at baseline, height-for-age Z-score, weight-for-age Z-score, weight-for-height Z-score and MUAC classified 777 (76·0 %), 630 (61·6 %), 131 (12·9 %) and eighty (7·8 %) children as moderately to severely malnourished, respectively. Over the 2-year study period, fifty-eight children (5·7 %) died. MUAC had the greatest AUC (0·68, 95 % CI 0·61, 0·75) and had the strongest association with mortality in this sample (hazard ratio = 2·21, 95 % CI 1·26, 3·89, P = 0·006).ConclusionsMUAC appears to be a better predictor of mortality than other anthropometric indicators in this community-based, high-malnutrition setting in Niger.
- Published
- 2020
35. CardioHPC: Serverless Approaches for Real-Time Heart Monitoring of Thousands of Patients.
- Author
-
Marjan Gusev, Sashko Ristov, Andrei Amza, Armin Hohenegger, Radu Prodan, Dimitar Mileski, Pano Gushev, and Goran Temelkov
- Published
- 2022
- Full Text
- View/download PDF
36. An Innovative Higher Education Institution Training Toolbox to Effectively Address Industry 4.0 Skills Gap and Mismatches
- Author
-
Francalanza, Emmanuel, Vella, Pierre, Rauch, Erwin, Amza, Catalin, Lundgren, Magnus, Putnik, Goran, Kacprzyk, Janusz, Series Editor, Gomide, Fernando, Advisory Editor, Kaynak, Okyay, Advisory Editor, Liu, Derong, Advisory Editor, Pedrycz, Witold, Advisory Editor, Polycarpou, Marios M., Advisory Editor, Rudas, Imre J., Advisory Editor, Wang, Jun, Advisory Editor, Matt, Dominik T., editor, Vidoni, Renato, editor, Rauch, Erwin, editor, and Dallasega, Patrick, editor
- Published
- 2022
- Full Text
- View/download PDF
37. ICARUS Pedagogical Methodologies Framework, or Reference Model
- Author
-
Putnik, Goran D., Alves, Cátia, Francalanza, Emmanuel, Borg, Jonathan, Amza, Catalin, Rauch, Erwin, Lundgren, Magnus, Varela, Leonilde, Pinheiro, Pedro, Kacprzyk, Janusz, Series Editor, Gomide, Fernando, Advisory Editor, Kaynak, Okyay, Advisory Editor, Liu, Derong, Advisory Editor, Pedrycz, Witold, Advisory Editor, Polycarpou, Marios M., Advisory Editor, Rudas, Imre J., Advisory Editor, Wang, Jun, Advisory Editor, Matt, Dominik T., editor, Vidoni, Renato, editor, Rauch, Erwin, editor, and Dallasega, Patrick, editor
- Published
- 2022
- Full Text
- View/download PDF
38. Mechanical Property Degradation of Polylactic Acid (PLA) 3D Printed Parts under Ultraviolet Radiation
- Author
-
Zapciu, Aurelian, Amza, Catalin Gheorghe, Ciolacu, Monica, Francalanza, Emmanuel, Rauch, Erwin, Kacprzyk, Janusz, Series Editor, Gomide, Fernando, Advisory Editor, Kaynak, Okyay, Advisory Editor, Liu, Derong, Advisory Editor, Pedrycz, Witold, Advisory Editor, Polycarpou, Marios M., Advisory Editor, Rudas, Imre J., Advisory Editor, Wang, Jun, Advisory Editor, Matt, Dominik T., editor, Vidoni, Renato, editor, Rauch, Erwin, editor, and Dallasega, Patrick, editor
- Published
- 2022
- Full Text
- View/download PDF
39. Die rumänische Außenpolitik nach 1989: vom policy taker zum policy shaper
- Author
-
Amza-András, Andrea, Lorenz, Astrid, editor, and Mariș, Daniela-Maria, editor
- Published
- 2022
- Full Text
- View/download PDF
40. Biannual versus annual mass azithromycin distribution and malaria seroepidemiology among preschool children in Niger: a sub-study of a cluster randomized trial.
- Author
-
Oldenburg, Catherine E, Amza, Abdou, Cooley, Gretchen, Kadri, Boubacar, Nassirou, Beido, Arnold, Benjamin F, Rosenthal, Philip J, O'Brien, Kieran S, West, Sheila K, Bailey, Robin L, Porco, Travis C, Keenan, Jeremy D, Lietman, Thomas M, and Martin, Diana L
- Subjects
Humans ,Malaria ,Azithromycin ,Merozoite Surface Protein 1 ,Antimalarials ,Prevalence ,Seroepidemiologic Studies ,Time Factors ,Child ,Preschool ,Infant ,Niger ,Female ,Male ,Mass Drug Administration ,Mass drug administration ,Microbiology ,Medical Microbiology ,Public Health and Health Services ,Tropical Medicine - Abstract
BackgroundBiannual mass azithromycin administration to preschool children reduces all-cause mortality, but the mechanism for the effect is not understood. Azithromycin has activity against malaria parasites, and malaria is a leading cause of child mortality in the Sahel. The effect of biannual versus annual azithromycin distribution for trachoma control on serological response to merozoite surface protein 1 (MSP-119), a surrogate for malaria incidence, was evaluated among children in Niger.MethodsMarkers of malaria exposure were measured in two arms of a factorial randomized controlled trial designed to evaluate targeted biannual azithromycin distribution to children under 12 years of age compared to annual azithromycin to the entire community for trachoma control (N = 12 communities per arm). Communities were treated for 36 months (6 versus 3 distributions). Dried blood spots were collected at 36 months among children ages 1-5 years, and MSP-119 antibody levels were assessed using a bead-based multiplex assay to measure malaria seroprevalence.ResultsAntibody results were available for 991 children. MSP-119 seropositivity was 62.7% in the biannual distribution arm compared to 68.7% in the annual arm (prevalence ratio 0.91, 95% CI 0.83 to 1.00). Mean semi-quantitative antibody levels were lower in the biannual distribution arm compared to the annual arm (mean difference - 0.39, 95% CI - 0.05 to - 0.72).ConclusionsTargeted biannual azithromycin distribution was associated with lower malaria seroprevalence compared to that in a population that received annual distribution. Trial Registration Clinicaltrials.gov NCT00792922.
- Published
- 2019
41. Telemedicine for Individuals with epilepsy: Recommendations from the International League Against Epilepsy Telemedicine Task Force
- Author
-
Samia, Pauline, Sahu, Jitendra Kumar, Ali, Amza, Caraballo, Roberto Horacio, Chan, Josephine, Coan, Ana Carolina, Fortini, Pablo Sebastián, Gwer, Samson, Jocic-Jakubi, Bosanka, Kissani, Najib, Rivera, Yanin, Sarfo, Fred Stephen, Singh, Mamta Bhushan, Trinka, Eugen, Yoo, Ji Yeoun, Yu, Hsiang-Yu, Zelano, Johan, and Cross, J.Helen
- Published
- 2023
- Full Text
- View/download PDF
42. Micropulse diode laser therapy in refractory glaucoma
- Author
-
Issiaka, Moctar, Zrikem, Khalil, Mchachi, Adil, Benhmidoune, Leila, Rachid, Rayad, Belhadji, Mohamed EL., Salam Youssoufou Souley, Abdoul, and Amza, Abdou
- Published
- 2023
- Full Text
- View/download PDF
43. Fostering Engineering Education 4.0 Paradigm Facing the Pandemic and VUCA World
- Author
-
Ciolacu, Monica Ioniță, Mihailescu, Bogdan, Rachbauer, Tamara, Hansen, Christina, Amza, Cătălin Gheorghe, and Svasta, Paul
- Published
- 2023
- Full Text
- View/download PDF
44. Epilepsy care delivery during COVID-19 in resource-limited countries: A survey in collaboration with International Epilepsy Equity Group
- Author
-
von Gaudecker, Jane R., Clarke, Dave F., Perkins, Susan, Ali, Amza, Sanjuan, Daniel, and Vidaurre, Jorge
- Published
- 2023
- Full Text
- View/download PDF
45. CHAPTER 13 Eqbal Ahmad: An Affective Reading of Afro-Asianism
- Author
-
Adam, Amza, primary
- Published
- 2022
- Full Text
- View/download PDF
46. The potential therapeutic value of terpenes
- Author
-
Lowe, Henry, primary, Ali, Amza, additional, Steele, Blair, additional, Gordon, Lorenzo, additional, and Grant, Justin, additional
- Published
- 2024
- Full Text
- View/download PDF
47. Assessment of spillover of antimicrobial resistance to untreated children 7 to 12 years old after mass drug administration of azithromycin for child survival in Niger: a secondary analysis of the MORDOR cluster-randomized trial
- Author
-
Peterson, Brittany, primary, Arzika, Ahmed M, additional, Amza, Abdou, additional, Maliki, Ramatou, additional, Mankara Karamba, Alio, additional, Moussa, Mariama, additional, Kemago, Mariama, additional, Liu, Zijun, additional, Houpt, Eric, additional, Liu, Jie, additional, Pholwat, Suporn, additional, Doan, Thuy, additional, Porco, Travis, additional, Keenan, Jeremy D, additional, Lietman, Thomas M, additional, and O’Brien, Kieran S, additional
- Published
- 2024
- Full Text
- View/download PDF
48. Efficacy of Single-Dose Azithromycin for Ocular Chlamydial Infection: A Longitudinal Study
- Author
-
Pondicherry, Neha, primary, Abdou, Amza, additional, Kadri, Boubacar, additional, Nassirou, Beido, additional, Cotter, Sun Y., additional, Varnado, Nicole E., additional, Porco, Travis C., additional, West, Sheila K., additional, Lietman, Thomas M., additional, and Keenan, Jeremy D., additional
- Published
- 2024
- Full Text
- View/download PDF
49. Clinical Considerations for Elderly Patients Undergoing Root Canal Treatment
- Author
-
Alexandru, Dimitriu Bogdan, primary, Ioana, Suciu, additional, Mihaela, Chirilă, additional, Florentina, Gheorghe Georgiana, additional, and Elena, Amza Oana, additional
- Published
- 2024
- Full Text
- View/download PDF
50. A multicentric, randomised, controlled clinical trial to study the impact of bedside model-informed precision dosing of vancomycin in critically ill children – BENEFICIAL trial
- Author
-
De Cock, Pieter Albert, primary, Colman, Roos, additional, Amza, Anca, additional, De Paepe, Peter, additional, De Pla, Hans, additional, Vanlanduyt, Lieselot, additional, and Linden, Dimitri Van Der, additional
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.